<p>Designing immunotherapeutics drugs and anti-inflammatory reagents has been at the forefront of autoimmune research in particular multiple sclerosis for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue focused on delivery methods to be used for vaccines immunotherapeutic approaches drug design and anti-inflammatories and their outcomes in preclinical studies and clinical trials.</p>